CytoSorb® haemoadsorption in high-risk cardiac surgery: A focused review with proposed tiered patient selection
Published online on May 14, 2026
Abstract
Perfusion, Ahead of Print.
Cardiopulmonary bypass (CPB) activates a well-characterised systemic inflammatory response that contributes substantially to postoperative morbidity and mortality, particularly in high-risk patient subgroups. CytoSorb® (CytoSorbents Corporation, Princeton,...
Cardiopulmonary bypass (CPB) activates a well-characterised systemic inflammatory response that contributes substantially to postoperative morbidity and mortality, particularly in high-risk patient subgroups. CytoSorb® (CytoSorbents Corporation, Princeton,...